Kymera Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
82.8M
on 2026-06-30, from 61.4M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
S-3ASR of 2024-10-31. Not read yet. S-3ASR ↗
$500.0M
TD Securities (USA), agreement of 2026-02-26. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
The 10-Q filed 2026-08-05 is not read yet.
Cash
11.7 quarters
$691.0M on 2026-06-30 ÷ $59.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2025-12-10 | Public offering | 7,000,000 | $86.00 | $602.0M | 424B5 ↗ |
| 2025-06-27 | Public offering incl. 0.66M pre-funded | 5,700,000 | $44.00 | $250.8M | 424B5 ↗ |